Incretin-based drugs are now being investigated and in some cases approved for a wide range of conditions, including cardiovascular disease, chronic kidney disease, sleep apnea, fatty liver disease (MASLD), neurodegenerative disorders, and even substance-use disorders
Food and Drug Administration (FDA)-approved semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro)
Hers GLP-1 offerings are FSA and HSA eligible and start at $199 per month, with medications like Ozempic costing $1,799 per month
I would guess eventually the compounds [including the personalized doses] wont be available
For type 2 diabetes mellitus, Retatrutide shows potential in improving glycemic control
B., Derving Karsbol, J